These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 18405845)

  • 1. Serotoninergic mechanisms in the treatment of obsessive-compulsive disorder.
    Goddard AW; Shekhar A; Whiteman AF; McDougle CJ
    Drug Discov Today; 2008 Apr; 13(7-8):325-32. PubMed ID: 18405845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacological treatments for obsessive-compulsive disorder and the serotonin-dopamine hypothesis].
    Okamoto Y
    Seishin Shinkeigaku Zasshi; 2011; 113(1):36-44. PubMed ID: 21404630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Memantine for treatment-resistant OCD.
    Poyurovsky M; Weizman R; Weizman A; Koran L
    Am J Psychiatry; 2005 Nov; 162(11):2191-2. PubMed ID: 16263867
    [No Abstract]   [Full Text] [Related]  

  • 4. Role of dopamine in the pathophysiology and treatment of obsessive-compulsive disorder.
    Koo MS; Kim EJ; Roh D; Kim CH
    Expert Rev Neurother; 2010 Feb; 10(2):275-90. PubMed ID: 20136383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Obsessive-compulsive disorder: implications of the efficacy of an SSRI, paroxetine.
    Ninan PT
    Psychopharmacol Bull; 2003; 37 Suppl 1():89-96. PubMed ID: 14566204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early onset of response with selective serotonin reuptake inhibitors in obsessive-compulsive disorder: a meta-analysis.
    Issari Y; Jakubovski E; Bartley CA; Pittenger C; Bloch MH
    J Clin Psychiatry; 2016 May; 77(5):e605-11. PubMed ID: 27249090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of dopamine in obsessive-compulsive disorder: preclinical and clinical evidence.
    Denys D; Zohar J; Westenberg HG
    J Clin Psychiatry; 2004; 65 Suppl 14():11-7. PubMed ID: 15554783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic Review and Meta-Analysis: Early Treatment Responses of Selective Serotonin Reuptake Inhibitors and Clomipramine in Pediatric Obsessive-Compulsive Disorder.
    Varigonda AL; Jakubovski E; Bloch MH
    J Am Acad Child Adolesc Psychiatry; 2016 Oct; 55(10):851-859.e2. PubMed ID: 27663940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reappraisal of spontaneous stereotypy in the deer mouse as an animal model of obsessive-compulsive disorder (OCD): response to escitalopram treatment and basal serotonin transporter (SERT) density.
    Wolmarans de W; Brand L; Stein DJ; Harvey BH
    Behav Brain Res; 2013 Nov; 256():545-53. PubMed ID: 24013013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder.
    McDougle CJ; Epperson CN; Pelton GH; Wasylink S; Price LH
    Arch Gen Psychiatry; 2000 Aug; 57(8):794-801. PubMed ID: 10920469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary, single-blind, prospective study.
    Pallanti S; Bernardi S; Antonini S; Singh N; Hollander E
    CNS Drugs; 2009 Dec; 23(12):1047-55. PubMed ID: 19958042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment-resistant anxiety disorders: A literature review of drug therapy strategies].
    Ammar G; Naja WJ; Pelissolo A
    Encephale; 2015 Jun; 41(3):260-5. PubMed ID: 25439852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Memantine augmentation for refractory obsessive-compulsive disorder.
    Pasquini M; Biondi M
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Aug; 30(6):1173-5. PubMed ID: 16730870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A single-blinded case-control study of memantine in severe obsessive-compulsive disorder.
    Stewart SE; Jenike EA; Hezel DM; Stack DE; Dodman NH; Shuster L; Jenike MA
    J Clin Psychopharmacol; 2010 Feb; 30(1):34-9. PubMed ID: 20075645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacologic management of obsessive-compulsive disorder.
    Jackson CW; Morton WA; Lydiard RB
    South Med J; 1994 Mar; 87(3):310-21. PubMed ID: 8134850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of tryptophan depletion on selective serotonin reuptake inhibitor-remitted patients with obsessive compulsive disorder.
    Hood SD; Broyd A; Robinson H; Lee J; Hudaib AR; Hince DA
    J Psychopharmacol; 2017 Dec; 31(12):1615-1623. PubMed ID: 29095069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Agomelatine augmentation in obsessive compulsive disorder: a preliminary report.
    Tzavellas E; Karaiskos D; Ilias I; Liappas I; Paparrigopoulos T
    Psychiatriki; 2014; 25(3):179-84. PubMed ID: 25367661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Obsessive-compulsive disorder: diagnostic and treatment issues.
    Stein DJ; Denys D; Gloster AT; Hollander E; Leckman JF; Rauch SL; Phillips KA
    Psychiatr Clin North Am; 2009 Sep; 32(3):665-85. PubMed ID: 19716996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparative, single-blind, randomized study on quetiapine and aripiperazole augmentation in treatment of selective serotonin reuptake inhibitor refractory obsessive-compulsive disorder.
    Talaei A; Hosseini FF; Aghili Z; Akhondzadeh S; Asadpour E; Mehramiz NJ; Forouzanfar F
    Can J Physiol Pharmacol; 2020 Apr; 98(4):236-242. PubMed ID: 32228235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic approaches to the treatment of refractory obsessive-compulsive disorder.
    Kochan LD; Qureshi AI; Fallon BA
    Curr Psychiatry Rep; 2000 Aug; 2(4):327-34. PubMed ID: 11122977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.